Definitions

• the present invention relates to a chemical composition for mgestion by humans and a method for aiding weight loss and reducing cholesterol levels m humans. More in particular, the chemical composition of the present invention is intended for mgestion by a human prior to eating a meal and will aid m the absorption and binding of undigested fat to at least one fibrous agent for rapid and natural elimination from the human body.
• a healthy body automatically secretes lipase, an enzyme that accelerates synthesis of fats, i.e., breaking down the fat molecule.
• lipase an enzyme that accelerates synthesis of fats, i.e., breaking down the fat molecule.
• the majority of all fats in foods are present "triglyce ⁇ de form", which the body seeks to break down by removing the glycerol molecule from the triglycende and thereby, release the free fatty acids. Once this occurs, the body is well on its way to absorbing the fat and likely, storing same instead of utilizing it for energy.
• any such product or method would permit the a person to eat the foods that they most like, while not being as mindful about the amount of fats contained therein, and further, would prevent the body from absorbing the fat such foods once they have been eaten Any such product and method would also ideally aid the body rapid elimination of the ingested fats m a safe, comfortable and natural manner. In turn, the rapid elimination of fats subsequent to mgestion and yet prior to digestion would have a highly beneficial effect in preventing the build-up or accumulation of harmful cholesterol.
• the present invention is designed to satisfy these and other needs which remain m the art and is believed to represent a significant advance in improving a person's health not only by facilitating weight loss but also the reduction of harmful cholesterol in humans, by means of the rapid elimination of fat from the human body.
• the present invention is directed to a novel chemical composition intended for mgestion by humans and a method which aids with weight loss and in reducing cholesterol m humans .
• the chemical composition of the present invention when the chemical composition of the present invention is ingested by a human prior to eating a meal, the composition acts to absorb and bind undigested fat to a fibrous agent so as to promote its rapid elimination from the human body.
• the novel composition is moisture activated such that it remains inert and can be formed into capsules, preferably conveniently sized for mgestion by a human, and will remain inert until it comes into contact with bodily secretions whether water or other liquid.
• the chemical composition of the present invention comprises a mixture of an amount of at least one fibrous agent, such as psyllium, at generally about 80% to 83% by weight, and amount of glucosamine, preferably glucosamine HCL, at generally about 8% to 10% by weight, and an amount of glucomannan generally about 5% to 6% by weight, and an amount of apple pectin generally about 2% by weight, and finally, also preferably an amount of stearic acid generally about 1% or 2% by weight of the composition.
• fibrous agent such as psyllium
• the chemical composition comprises at least one fibrous agent, preferably psyllium, at generally between 48% and 52% by weight, and an amount of glucosamine, preferably glucosamine HCL, at generally between 38% and 42% by weight, and an amount of glucomannan at generally between 5% and 6% by weight, and an amount of fruit or vegetable derived pectin, such as apple pectin, at generally about 2% by weight, and finally, preferably also an amount of stearic acid at generally between 1% and 2% by weight of the composition.
• the chemical composition comprises a mixture of an amount of at least one fibrous agent, such as psyllium, at generally about 85% by weight, and an amount of glucosamine, also preferably glucosamine
• HCL HCL
• glucomannan at generally about 5% and 6% by weight
• fruit or vegetable derived pectin such as apple pectin
• stearic acid generally between 1% and 2% by weight of the composition.
• a method for using the chemical composition comprises the steps of forming a capsule of generally about five hundred milligrams (500mg) which contains the chemical composition of the first and second preferred embodiments, and having a human ingest at least one of said capsules, preferably with about eight ounces of water about fifteen minutes or twenty minutes before each meal.
• the method for using the chemical composition for reducing cholesterol comprises the steps of forming a single dose capsule of preferably about seven hundred milligrams (700 mg) which contains the chemical composition of the third preferred embodiment, described above, and having a human ingest at least four of such capsules, preferably with about eight ounces of water between fifteen and twenty minutes prior to each meal.
• this alternative preferred method includes having a human ingest substantially about twenty-eight hundred milligrams (2800 mg) of the composition before each meal, and contemplates three meals per day, which is believed to offer compelling results reducing the cholesterol levels of a human following the steps of the method. These results would only be enhanced if a diet low fatty foods and a regimen of regular exercise were also followed.
• a primary object of the present invention is to provide a convenient and effective means for aiding weight loss m a human which safely affects only the fat portion of foods ingested by the human without affecting metabolism.
• Another primary object of the present invention is to provide a chemical composition and method of treatment which serve as convenient and effective means for reducing the quantity of fat digested and/or absorbed by the human body, thereby aiding m a significant reduction of harmful cholesterol and the build-up or collection of cholesterol deposits the cardio-vascular system.
• Yet another primary object of the present invention is to provide a chemical composition which seeks out, attaches and binds undigested fat ingested by a human to a fibrous agent, forming an undigestible mass which can easily and rapidly be eliminated from the human ' s body.
• a feature of the chemical composition according to the present invention is that moisture activated and therefore, is inert and can be formed into and stored as conveniently sized capsules until being ingested by a human and activated by coming into contact with bodily secretions whether water or other liquid.
• Yet another object of the present invention is to provide a chemical composition which includes a blend of fibrous material for aiding the human body m rapid elimination of waste.
• a feature of the present invention in the form of one 500 milligram capsule is that it can absorb at least five times its own weight of undigested fats.
• the present invention is directed towards a chemical composition and method of treatment utilizing the chemical composition which acts to absorb and bind undigested fat and rapidly eliminate the fat through the normal passage of waste from the human body prior to digestion or absorption of the fat.
• the present invention is also directed to a method of significantly reducing the production and cardio-vascular build-up of harmful cholesterol humans .
• the chemical composition of the present invention primarily comprises at least one fibrous agent to act both as a vehicle for absorbing fat and as a medium for allowing a human to feel full.
• the fibrous agent used is psyllium and comprises generally between 80% and 90% by weight of the composition.
• psyllium comprises generally about or between 80% to 83% by weight of the composition
• m another alternative embodiment, intended to aid with reducing cholesterol, the psyllium comprises generally about 84% - 85% by weight of the composition.
• the chemical composition comprises generally between 48% and 52% by weight of psyllium, and more preferably, about fifty percent (50%) of psyllium.
• composition of the present invention may additionally comprise one or more other fibrous agents, which may be in addition to psyllium.
• other fibrous agents may be utilized, which are very fibrous materials.
• Other fibrous agents may also be utilized, as described more fully below.
• composition of the present invention preferably also comprises glucosamine, a material derived from deacetylated shellfish shells or chitin.
• Chitin is known in the art as a naturally occurring polysaccharide
• glucosamine may be obtained from chitin by hydrolysis.
• glucosamine salts and compounds derived from a monomer of chitin namely, N-acetyl-D- glucosamine (GlcN Ac) which is represented by the general formula:
• glucosamine hydrochloride acetylated glucosamines, and/or D-glucosamine .
• glucosamine HCL and/or glucosamine hydrochloride will be utilized and will comprise m a first preferred embodiment, generally between eight and ten percent (8% to 10%) by weight of the composition.
• the amount of glucosamine or glucosamine HCL m the chemical composition will generally between 38% and 42% by weight, and ideally, about forty percent (40%) by weight of the composition.
• the amount of glucosamine or glucosamine HCL m the chemical composition will generally be about six or seven percent (6% - 7%) by weight of the composition.
• the use of glucosamine hydrochloride in the composition offers an additional side benefit in that it has been shown to be an efficacious alternative to corticosteroid treatment of enteritis and colonitis.
• glucosamine HCL is an ion, or molecule having a negative charge, and which therefore, attracts and binds with certain molecules of food.
• a beta- alkylglycoside of N-acetyl-D-glucosamme may be utilized, which is represented by the general formula:
• the composition may comprise chitosan, instead of glucosamine, m amounts similar to those described above with respect to glucosamine and/or glucosamine HCL.
• Chitosan is formed by dunking the chitin, m its white powder form, in a concentrated sodium hydroxide solution heated to above 135 degrees Celsius to remove one of chitin' s side groups, i.e., to hydrolyze the N-acetyl linkage, such that chitosan results, which can be more readily dissolved.
• Chitosan which is represented by the general formula:
• the chemical composition comprises, in addition to psyllium and glucosamine or glucosamine HCL, a quantity of glucomannan -- also known as Konjak or Konjac Root -- which serves the purpose of providing lubrication and as well as providing an additional fibrous agent to the composition.
• glucomannan comprises generally about 5% to 6% by weight of the composition.
• the chemical composition preferably also comprises a pectin derived from fruits or succulent vegetables which serves the purpose of providing an additional fibrous agent to the composition so as to aid the user with feeling "full".
• an apple pectin is used to form the composition which ideally, comprises generally about 2% by weight of the composition.
• the chemical composition also comprises a saturated fatty acid such as stearic acid, which serves the purpose of permitting the capsule containing the composition to be smooth and/or of facilitating the formation of the capsule containing the inventive composition.
• a saturated fatty acid such as stearic acid
• the stearic acid utilized will comprise generally about 1% or 2% by weight of the composition.
• the psyllium, glucosamine HCL, glucomannan, apple pectin and stearic acid are mixed together in powder form, although a granular form might also be suitable, and result in a mixture which is inert until it comes into contact with water, or another liquid such as is produced by the human body during digestion.
• the present invention can be formed into capsules for being easily packaged and stored. Additionally, the material used to form the encasement of the capsule will be inert and upon coming into contact with water or other liquid, will begin to break down and permit both the release and activation of the chemical composition.
• Capsules also have the advantage of dissolving m a shorter period of time, thereby exposing the chemical composition to ingested fat in a shorter amount of time after mgestion.
• Single doses of the composition could also be formed, however, into pills which would simply require mgestion by humans at a longer period of time before meals are consumed.
• the capsules containing the chemical composition according to the present invention may be packaged into bottles containing 50, 60, 75, 80, 100 or more capsules, and may include a small, separately wrapped quantity of a drying agent, such as a silica gel in order to assume a dry storage environment desirable for preserving the inertness of the composition until use.
• the chemical composition of the present invention will be formed into capsules containing generally about 500 milligrams of the chemical composition m the following amounts: generally about 80% or 83% by weight of psyllium; generally about 8% or 10% by weight of glucosamine HCL; generally about 5% or 6% by weight of glucomannan; generally about 2% by weight of apple pectm; and generally about 1% or 2% by weight of stearic acid.
• the chemical composition will also be formed into capsules containing generally about 500 milligrams of the chemical composition m the following amounts: generally about fifty percent (50%) by weight of psyllium, generally about forty percent (40%) by weight of glucosamine, preferably glucosamine HCL, generally between 5% and 6% by weight of glucomannan, and generally about 2% by weight of fruit or vegetable derived pectm, such as apple pectm, and generally about 1% or 2% by weight of stearic acid.
• psyllium generally about forty percent (40%) by weight of glucosamine, preferably glucosamine HCL, generally between 5% and 6% by weight of glucomannan, and generally about 2% by weight of fruit or vegetable derived pectm, such as apple pectm, and generally about 1% or 2% by weight of stearic acid.
• glucosamine HCL generally between 5% and 6% by weight of glucomannan
• a capsule containing about 500 milligrams has a size and overall dimension which is readily suited for being comfortably swallowed by a person, although the capsule could be formed to be contain less or more of the chemical composition (with ratios of the composition similar to that disclosed herein) , and thereby be somewhat larger or smaller, and still function for being ingested by a person.
• Testing experiments with the above described chemical composition have demonstrated the ability to absorb at least five (5) times its own weight of undigested fats. For instance, m one experiment 70 milliliters of water was placed in an appropriately sized test tube along with 10 grams (10,000mg) of wheat germ oil and 100 milligrams of lecithin. This mixture was shaken vigorously for about 10 seconds.
• the chemical composition of the present invention seeks out and binds with fat ingested by a human prior to its being absorbed into the body, and as has been explained, binds them to a fibrous agent so as to aid the person in feeling "full” and further, to permit rapid elimination by the human body.
• one preferred method of the present invention comprises the steps of forming a capsule of generally about 500 milligrams with the chemical composition and having the human mgest at least one of the 500 milligram capsules with generally about eight ounces of water generally about fifteen to twenty minutes before a meal.
• the human will mgest two of the capsules before each meal, but may mgest up to about four of the capsules (2000 milligrams) if the meal to be eaten is especially large and/or has a particularly high fat content.
• each capsule Upon being ingested by a human, each capsule begins to disintegrate and releases or otherwise facilitates activation of the chemical composition contained therein in typically, generally about thirty (30) minutes, and often less time.
• the present invention will be formed into capsules containing generally about seven hundred milligrams (700 mgs) of the chemical composition in the following amounts: generally about 85% by weight of psyllium; generally about 6% by weight of glucosamine HCL; generally about 6% by weight of glucomannan; generally about 2% by weight of apple pectin; and generally about 1% by weight of stearic acid.
• a capsule containing about 700 milligrams has a size and overall dimension which is readily suited for being comfortably swallowed by a person in quantities corresponding to recommended doses.
• the capsule could be formed to contain less or more of the chemical composition (with ratios of the composition similar to that disclosed therein) , and thereby be somewhat larger or smaller, and still be adequate for ingestion by a person.
• This alternative embodiment of the chemical composition lends itself to a method for reducing cholesterol, which will now be described.
• another preferred method of the present invention comprises the steps of forming a capsule of generally about 700 milligrams with the chemical composition and having the human ingest at least four of the 700 milligram capsules with generally about eight ounces of water about fifteen to twenty minutes before a meal. Ideally however, the human will ingest four of the capsules before each meal, with three meals per day being eaten.
• the intake of psyllium with each capsule is generally about six hundred milligrams (600 mgs) or multiplying by four, twenty-four hundred milligrams (2400 mgs) per meal, and if three meals a day are eaten, the intake would then be seventy-two hundred milligrams (7200 mgs) of psyllium per day, which amount has been shown to significantly aid with reducing cholesterol. From the foregoing, it should be clear that the human may ingest more than four such capsules, e.g., up to about six or more of the capsules if the meal to be eaten is especially large and/or has a particularly high fat content.
• each capsule Upon being ingested by a human, each capsule also begins to disintegrate and releases or otherwise facilitates activation of the chemical composition contained therein in typically, generally about thirty (30) minutes, and often less time.

Landscapes

• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Plant Substances (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (1)

Publications (2)

Family

ID=22267691

Family Applications (1)

Country Status (4)

Families Citing this family (1)

• 1998
  • 1998-08-18 JP JP2000565906A patent/JP2002523373A/ja active Pending
  • 1998-08-18 EP EP98943227A patent/EP1105144A4/de not_active Withdrawn
  • 1998-08-18 MX MXPA01001802A patent/MXPA01001802A/es unknown
• 2002
  • 2002-03-25 HK HK02102239.5A patent/HK1040630B/zh not_active IP Right Cessation

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events